Wild-type KRAS organoid lines of HCC were sensitive to the EGF receptor inhibitor AZD8931, while organoids harboring mutated KRAS were resistant, suggesting guidance for personalized medicine based on tumor heterogeneity29. Here, KRAS is linked to neoplasm.